PolyPid
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
18 Hasivim St, Petah Tiqwa, Central Dist...Phone Number
+972 747195700Website
www.polypid.comRevenue
$25.8 MillionStock Symbol
PYPDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.Explore more
PolyPid Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PolyPid your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if PolyPid had a recent Job posting/layoffs
Check out if PolyPid is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if PolyPid has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when PolyPid launches new products
Congratulate Masked Content for being promoted to Masked Content at PolyPid
PolyPid, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once PolyPid has new funding data
Earning: See what the market has to say on PolyPid recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
PolyPid is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PolyPid is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PolyPid.
PolyPid financials insights
Gather financial insights about PolyPid, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$2.2M
2014
Series B
$10.9M
2015
Series C
$8.3M
2016
Series D
$22M
Private Equity
$5.3M
2019
Series E
$50M
2024
Debt
$14.5M
2025
Stock/Share Issuance
$26.7M
PolyPid Tech Stack
A closer look at the technologies used by PolyPid
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
PolyPid has developed D-PLEX100, a product that pairs the company's PLEX platform with doxycycline for 30-day coverage of surgical incisions to prevent infections. The company is in the process of submitting an NDA application following positive Phase 3 data from a pivotal study.
Product Development, Medical Research, Pharmaceuticals
Project
PolyPid has announced that the initial target market for D-PLEX100 is abdominal surgery, accounting for about 4.4 million procedures annually in the U.S. and an additional 3 million in Europe, totaling 7.4 million operations.
Business Intelligence, Analytics & Insights
Award
PolyPid has announced that its product has received Breakthrough Therapy designation and three different Qualified Infectious Disease Product (QIDP) designations, making it eligible for the ENTER program, which could provide up to 75% reimbursement on the cost of the drug in the first two to three years from launch.
Pharmaceuticals, Finance, Financial Operations, Healthcare Operations
Project
Product Development, Medical Research, Pharmaceuticals
PolyPid News & Media
Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid
Woburn, MA, July 21, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today announced plans to commercialize D-PLEX100 upon approval in the United States and Canada for the prevention of abdominal colorectal surgical site infections (“SSIs”) in partnership with PolyPid Ltd. (“PolyPid”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, who will manufacture and supply D-PLEX100.PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PETACH TIKVA, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the “Agreement”) with Azurity Pharmaceuticals (“Azurity”), a privately held specialty pharmaceutical company, for the commercialization of D-PLEX100 in the United States and Canada forPolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infectionsPolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company’s management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PolyPid
Sign Up For FreeTo access detailed company insights
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal rel... Read More
